These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
180 related items for PubMed ID: 8228082
21. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)]. Maier K, Fischer C, Klotz U, Heinkel K. Dtsch Med Wochenschr; 1982 Jul 23; 107(29-30):1131-4. PubMed ID: 6123426 [Abstract] [Full Text] [Related]
22. Asacol (mesalamine). Claussen D. Gastroenterol Nurs; 1992 Aug 23; 15(1):33-4. PubMed ID: 1525190 [Abstract] [Full Text] [Related]
23. Sulfasalazine and new analogues in inflammatory bowel disease, with focus on Crohn's disease. van Hees PA. Acta Gastroenterol Belg; 1987 Aug 23; 50(5):555-9. PubMed ID: 2902723 [No Abstract] [Full Text] [Related]
24. [Exacerbation of ulcerative colitis and Crohn's disease following a change-over from salazosulfapyridine to 5-aminosalicylic acid]. Feurle GE, Helmstädter V. Dtsch Med Wochenschr; 1986 May 02; 111(18):721-2. PubMed ID: 2870908 [No Abstract] [Full Text] [Related]
25. Controversies with aminosalicylates in inflammatory bowel disease. Lim WC, Hanauer SB. Rev Gastroenterol Disord; 2004 May 02; 4(3):104-17. PubMed ID: 15359211 [Abstract] [Full Text] [Related]
26. Drug insight: aminosalicylates for the treatment of IBD. Nielsen OH, Munck LK. Nat Clin Pract Gastroenterol Hepatol; 2007 Mar 02; 4(3):160-70. PubMed ID: 17339853 [Abstract] [Full Text] [Related]
27. Medical management of patients with difficult-to-treat inflammatory bowel disease. van Hogezand RA. Neth J Med; 1994 Aug 02; 45(2):55-9. PubMed ID: 7936006 [Abstract] [Full Text] [Related]
28. [Drug treatment of chronic inflammatory intestinal diseases with special reference to 5-azosalicylic acid]. Fahrländer H. Schweiz Med Wochenschr; 1987 Oct 17; 117(42):1620-3. PubMed ID: 3321418 [Abstract] [Full Text] [Related]
29. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine. Nakajima H, Munakata A, Yoshida Y. J Gastroenterol; 1995 Nov 17; 30 Suppl 8():115-7. PubMed ID: 8563870 [Abstract] [Full Text] [Related]
30. [Current therapeutic possibilities in chronic inflammatory intestinal diseases]. Schölmerich J. Praxis (Bern 1994); 1995 Jan 10; 84(2):29-33. PubMed ID: 7839043 [Abstract] [Full Text] [Related]
31. Sulfasalazine and 5-ASA compounds. Allgayer H. Gastroenterol Clin North Am; 1992 Sep 10; 21(3):643-58. PubMed ID: 1355468 [Abstract] [Full Text] [Related]
32. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease. Clemett D, Markham A. Drugs; 2000 Apr 10; 59(4):929-56. PubMed ID: 10804042 [Abstract] [Full Text] [Related]
35. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. Klotz U, Maier K, Fischer C, Heinkel K. N Engl J Med; 1980 Dec 25; 303(26):1499-502. PubMed ID: 6107853 [Abstract] [Full Text] [Related]